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2Abstract. Researchers are often interested in treatment effects on outcomes that are
only defined conditional on a post-treatment event status. For example, in a study of
the effect of different cancer treatments on quality of life at end of follow-up, the quality
of life of individuals who die during the study is undefined. In these settings, a naive
contrast of outcomes conditional on the post-treatment variable is not an average causal
effect, even in a randomized experiment. Therefore the effect in the principal stratum of
those who would have the same value of the post-treatment variable regardless of treat-
ment, such as the always survivors in a truncation by death setting, is often advocated
for causal inference. While this principal stratum effect is a well defined causal contrast,
it is often hard to justify that it is relevant to scientists, patients or policy makers, and
it cannot be identified without relying on unfalsifiable assumptions. Here we formulate
alternative estimands, the conditional separable effects, that have a natural causal in-
terpretation under assumptions that can be falsified in a randomized experiment. We
provide identification results and introduce different estimators, including a doubly ro-
bust estimator derived from the nonparametric influence function. As an illustration,
we estimate a conditional separable effect of chemotherapies on quality of life in patients
with prostate cancer, using data from a randomized clinical trial.
1. Introduction
Many research questions involve treatment effects on outcomes that are only defined
conditional on a post-treatment event status. For example, in a study of the effects of
different cancer treatments on quality of life at end of follow-up, the quality of life of
individuals who die during the study is undefined. Furthermore, some treatment effects
are only of substantive interest conditional on a post-treatment event. In a study of the
effect of a vaccine on viral load at end of follow-up, the viral load of individuals who
never become infected is not of substantive interest (even though it is defined).
By design of a randomized trial, we can identify a counterfactual contrast of mean
outcomes across treatment arms conditional on a post-treatment status (when there are
no losses to follow-up). However, this contrast does not in general equal a causal effect
3when the treatment affects the post-treatment event. In this case, outcomes are being
compared in different sets of individuals, and thus the comparison cannot be interpreted
as a contrast of (counterfactual) outcomes in the same set of individuals under different
treatment conditions. For example, when the cancer treatments affect survival, the subset
of the population who would survive under one treatment will be different from the subset
who would survive under the other treatment.
Selecting a meaningful definition of a causal effect in this setting is not straightforward.
One option is to consider a so-called controlled direct effect [1], which quantifies the effect
of the treatment on the outcome had we (somehow) eliminated post-treatment events that
render the outcome undefined or not of substantive interest. However, such effects often
do not quantify effects of interest to an investigator, policy maker, doctor or patient; for
example, the utility of the effect of a cancer treatment on quality of life had we eliminated
death, or the effect of a vaccine on viral load had we forced everyone to become infected,
is not clear.
Given the limitations of the controlled direct effect, Robins [2] introduced the principal
stratum effects in settings where the outcome of interest is only defined, or of substantive
interest, conditional on a post-treatment event status; in particular, the causal effect in
the subset of individuals who would have this event status, regardless of the treatment
they were given. The name “principal stratum effect” is due to Frangakis and Rubin
[3] who, in contrast to Robins’s [2] more skeptical view, advocated strongly for the use
of this estimand. Indeed, it has been argued that no other sensible causal estimand
exists in this case [4, 5, 6]. However, principal stratum effects also have several serious
limitations [2, 7, 8, 9, 10]. It is impossible to observe the individuals in this subset of
the population because it is defined by the event status in the same individual under
different treatments. Further, this subset may not actually exist and, if it does exist,
may constitute a highly unusual subset of the original population. Finally, identification
4of a principal stratum effect generally relies on assumptions that cannot be falsified in
any real-world experiment.
Here we provide new definitions of causal effects for settings where the outcome is
only defined or of substantive interest conditional on a particular post-treatment event
status: the conditional separable effects. These estimands are inspired by Robins and
Richardson’s treatment decomposition in the context of mediation [10] and the (marginal)
separable effects for competing events settings [11, 12]. Unlike principal stratum effects,
the conditional separable effects rely only on assumptions that can be falsified in future
real-world experiments. Among these is a simple isolation condition which ensures that
(i) the conditional separable effects quantify meaningful direct effects of the treatment on
the outcome in a particular subset of the population and (ii) the individuals comprising
this subset can be identified.
Regardless of whether the isolation condition holds, we argue that critical thinking
about this condition is essential when the outcome is undefined or not of substantive
interest conditional on a post-treatment event status. In particular, we argue that, when
it fails, it is not clear that a meaningful notion of this conditional effect exists. Finally, we
show that, given this isolation condition, a conditional separable effect equals a principal
stratum effect under an additional monotonicity condition.
The manuscript is organized as follows. In Section 2 we describe the observed data
structure. In Section 3, we review the interpretation and identification of conventional
principal stratum effects. In Section 4, we define the conditional separable effects and dis-
cuss their interpretation under the isolation condition. In Section 5, we define a modified
treatment assumption [12], allowing the conditional separable effects to explain mech-
anism of the original treatment under study. In Section 6 we discuss the need for the
isolation condition and modified treatment assumption in order to define a meaningful
effect of the original treatment on the outcome in this setting and give an example. In
Section 7, we define conditions that are sufficient to identify the conditional separable
5effects with the observed data, provide an identification formula, and give new identifi-
cation results for classical principal stratum estimands in the presence of time-varying
common causes of the outcome of interest and the conditioning event. In Section 8, we
describe different estimators of the conditional separable effect, including a doubly ro-
bust estimator based on the nonparametric influence function. In Section 9, we apply our
results to understand the effect of different chemotherapies on quality of life in patients
with prostate cancer. In Section 10, we end with a discussion.
2. Observed Data
Consider a randomized experiment with n i.i.d. individuals who are assigned a binary
treatment A ∈ {0, 1} at baseline. Let k ∈ {0, . . . , K + 1} index equally spaced discrete
time intervals, and Y ≡ YK+1 is the outcome of interest measured in K +1. Let Dk+1 be
an indicator of post-treatment event status by k + 1, such that Y is only defined, or is
only of substantial interest, when Dk+1 = 0, k ∈ {0, . . . , K}. For example, in our running
example on cancer treatment and quality of life, Dk+1 is an indicator of death by k + 1.
In our other example on vaccination and viral load, Dk+1 is an indicator of not becoming
infected by k + 1.
Let L0 denote a vector of pre-randomization (baseline) covariates, and Lk a vector
of post-randomization (time-varying) covariates measured at k. We adopt the temporal
convention (L0, A, . . . , Dk, Lk, . . . , DK+1, Y ), with this assumption arbitrary as interval
lengths become infintesimally small. We use overbars (e.g. Dk+1) to denote the history
and underbars (e.g. Dk+1) to denote the future of a random variable relative to k + 1,
respectively. We assume that no subject is lost to follow-up throughout the main text
but extend all results to settings with loss to follow-up (censoring) in Appendix A.
63. Challenges in interpretation and identification of principal stratum
effects
For any individual in the study population, let Y a and Dak+1, k ∈ {0, . . . , K}, denote
the counterfactual outcome of interest and the post-treatment event indicator by k + 1,
respectively, had she been assigned to A = a. The following additive principal stratum
effect
E(Y a=1 − Y a=0 | Da=1K+1 = D
a=0
K+1 = 0)(1)
is the effect of the treatment A on Y in the subset of individuals who would never
experience the post-treatment event rendering Y undefined/not of interest under any
level of treatment [3, 2]. Because the conditioning set in (1) is defined by outcomes under
different counterfactual treatments, it is impossible to observe the individuals in this
subset of the population [2], which clearly limits its practical relevance [7, 8, 9]. Further,
we are not guaranteed that this unknown subset of the population exists and, if it does
exist, it may constitute a highly unusual subset of the original study population.
Returning to our cancer treatment example, (1) is the effect of cancer treatment on
quality of life at end of follow-up among those who would survive throughout the study
regardless of what cancer treatment they received. This may be a highly unusual sub-
group, particularly if a = 0 refers to no treatment. Similarly, in our vaccine example,
(1) is the effect of receiving the vaccine on viral load at end of follow-up among those
who would become infected regardless of whether they received the vaccine. For an effec-
tive vaccine, this subgroup may constitute a small and unusual segment of the original
population (which, again, cannot be observed).
In addition to these interpretational challenges, strong assumptions are required for
identification of principal stratum effects like (1) [4, 2, 7, 13, 14], even in idealized settings
with a randomly assigned point treatment, no loss to follow-up and no common causes
of Y and D1 as represented in the causal directed acyclic graph (DAG) [15] in Figure
71a. Throughout, we will use causal DAGs to represent underlying assumptions on how
random variables in a particular study are generated (including counterfactual random
variables below). Specifically our causal DAGs represent an underlying Finest Fully
Randomized Causally Interpreted Structural Tree Graph (FFRCISTG) model (as fine as
the data) [2, 16], which is a counterfactual causal model that predates and makes fewer
assumptions than the perhaps more familiar non-parametric structural equation model
with independent errors (NPSEM-IE) [10, 15, 16]. The absence of an arrow on a causal
DAG will be used to represent the assumption that an individual-level causal effect is
absent for every subject.
A causal DAG must minimally represent all common causes of any variable represented
on the DAG. Therefore, Figure 1a represents a generally restrictive assumption on the
study data generating process because it depicts no common causes (measured or un-
measured) of D1 and Y , which cannot be guaranteed even in a perfectly executed trial.
Only a handful of authors have considered identification of principal stratum effects when
common causes of the conditioning event and the outcome of interest exist and may be
affected by treatment [14, 17]; this more realistic data generating assumption is repre-
sented in Figure 2a. Further, previously posed identification strategies for (1) have relied
on unfalsifiable assumptions; that is, assumptions that can never be challenged in any
plausible experiment.
In the sections that follow, we will introduce new counterfactual estimands that over-
come these limitations of principal stratum effects. These estimands can in principle be
identified by design in a future real-world experiment. Further, under a set of additional
assumptions, that are falsifiable in such an experiment, these new estimands can be iden-
tified in a current experiment or observational study and capture a meaningful notion
of treatment mechanism in an identified subset of the original study population. These
assumptions are compatible with the existence of common causes (possibly affected by
treatment) of the conditioning event and the outcome of interest. Finally, we show that
8under one additional assumption, these estimands happen to equal a principal stratum
effect such as (1).
4. The Conditional Separable Effects
Following Robins et al [10, 18] in a mediation context and Stensrud et al [11, 12],
suppose a four arm trial could be plausibly conducted such that, in place of assignment
to one of the two values of A as in Section 2, individuals are jointly assigned values
of two new treatments AY ∈ {0, 1} and AD ∈ {0, 1}. Let Y
aY ,aD and DaY ,aDk+1 denote
the counterfactual outcome of interest and the post-treatment event indicator by k + 1,
respectively, had an individual been assigned AY = aY and AD = aD for aY and aD
possible realizations of AY and AD, respectively. We denote this four arm trial by G.
Consider the following condition relative to a causal DAG representing the assumed data
generating mechanism under G,
there are no causal paths from AY (G) to Dk+1(G), k ∈ {0, ..., K},(2)
where any node V (G) represented on the DAG denotes a random variable V under the
treatment assignment in G. Like the causal DAG representing the data generating mech-
anism for the current study of Section 2 (e.g. Figure 1a), the causal DAG representing
the mechanism for the future trial G (e.g. Figure 1b) relies on subject matter exper-
tise/assumptions relative to a particular choice of treatments AY and AD.
Following Stensrud et al [12], we refer to condition (2) as the assumption of AY par-
tial isolation 1. AY partial isolation is illustrated in the causal DAGs of Figure 1b and
Figures 2b-c (with the index G suppressed in the latter and in subsequently presented
1In the mediation context, Robins and Richardson [10, Section 6.1] provided (using different nomencla-
ture) examples of AY partial isolation (their Figure 6a) and the related conditions AD partial isolation
(their Fig 6.b) and full isolation (their Figure 4) (see also Stensrud [12] and Section 6.2 in this article).
Robins and Richardson showed identification of the marginal distribution of Y aD ,aY , for aD 6= aY ,under
the assumptions that A was randomly assigned and (5) held. However they showed the identifying formu-
las depended on whether the true causal DAG satisfied AY versus AD partial isolation. In contrast to the
current paper Robins and Richardson [10, Section 6.1] did not consider interpretation and identification
of conditional effects.
9causal DAGs under G to avoid clutter). By contrast, AY partial isolation fails in Figure
2d due to the path AY (G) → Z1(G) → Y (G). In a causal DAG [15, 10], AY partial
isolation (2) ensures that DaY ,aDk+1 = D
aD
k+1, ∀aY , aD ∈ {0, 1} and ∀k ∈ {0, . . . , K} where
DaDk+1 denotes the counterfactual value of the post-treatment event indicator by k + 1,
had an individual been assigned AD = aD and the natural value of AY [16]. In other
words, AY partial isolation ensures that the treatment AY does not directly or indi-
rectly affect the post-treatment event by any k + 1. Importantly, AY partial isolation is
a falsifiable assumption. For example, we can observe in the future 4-arm trial G whether
E [Dk+1(G) | AY (G) = 1, AD(G) = aD] = E [Dk+1(G) | AY (G) = 0, AD(G) = aD] , k = 0, ..., K,
and aD = {0, 1}, with failure of this equality falsifying AY partial isolation.
The relation between AY partial isolation in a causal DAG representing an underly-
ing FFRCISTG model and the equality DaY ,aDk+1 = D
aD
k+1 can be more explicitly seen by
minimal counterfactual labelling in a Single World Intervention Graph (SWIG), which
explicitly depicts counterfactual variables [16]. For example, Figure 3a depicts a SWIG
that is a transformation of the causal DAG in Figure 2c, consistent with AY partial iso-
lation, under an intervention that sets AY to aY and AD to aD. Minimal labelling allows
removal of the aY superscript on the counterfactual values under intervention of both Z1
and D2. By contrast, minimal labelling does not allow removal of this aY superscript in
Figure 3b which is a corresponding transformation of the causal DAG in 2d consistent
with failure of AY partial isolation.
Under AY partial isolation, the following counterfactual contrast
E(Y aY =1,aD − Y aY =0,aD | DaDK+1 = 0)(3)
is the average causal effect of the treatment AY on Y when all individuals are assigned
AD = aD, in the subset of individuals who do not experience the post-treatment event
under AD = aD, regardless of the value of AY they are assigned. Thus, under AY partial
isolation this subset of individuals can be directly observed in a study that assigns AY and
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AD as simply the subset of individuals who do not experience the post-treatment event
among all those receiving AD = aD. This is in contrast to the unobservable subset of
individuals who define the principal stratum effect (1). We refer to (3) as the conditional
separable effect evaluated at aD ∈ {0, 1}. We take the assumption of AY partial isolation
as given throughout the remainder of this manuscript, unless otherwise stated. In Section
(6) we will argue that this assumption is required to meaningfully define an effect of A
on Y conditional on DK+1 = 0.
In Section 6.1, we discuss two future treatments AY and AD consistent with the as-
sumption of AY partial isolation (2) in the cancer and quality of life example. Provided
that these treatments are defined such that they can plausibly be developed and assigned
in a future trial G, the conditional separable effect evaluated at AD = aD is identified by
design in that trial and trivially estimated by the mean difference in outcomes in the arm
assigned AY = 1 and AD = aD versus AY = 0 and AD = aD, among all those in these
two arms not experiencing the post-treatment event.
5. The Modified Treatment Assumption
We now give conditions under which the conditional separable effects provide an ex-
planation of the mechanism by which the original treatment A affects Y . Consider two
studies: the current study where A is randomly assigned and a future study where AY
and AD are jointly assigned. Following Stensrud et al [12, Appendix A], for two variables
MY and MD, suppose that the following conditions hold in these two studies:
All effects of A,AY and AD on Y and Dk, k ∈ {0, K}, are intersected by
MY and MD, respectively, and
M
aY =a,aD
Y = M
a
Y for aD ∈ {0, 1}
M
aY ,aD=a
D = M
a
D for aY ∈ {0, 1},(4)
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We refer to (4) as the modified treatment assumption. It follows from (4) that jointly
assigning AY and AD to the same value a leads to exactly the same values of Y and
Dk+1, k ∈ {0, K} as assigning A to a. Robins and Richardson [10] introduced a decom-
position assumption that is covered by our modified treatment assumption (4): let the
treatments AY and AD constitute a decomposition of A such that A exerts all its effects
on Y and DK+1 through AY and AD, and the following determinism holds in the current
study,
A ≡ AD ≡ AY .(5)
Their decomposition assumption is a special case of (4) by defining AY ≡ MY and
AD ≡ MD. We can consider an example where (4) holds but not their decomposition
assumption. Suppose that an old chemotherapeutic treatment (A = 1) has an unpleasant
side-effect that reduces quality of life compared to no treatment (A = 0): it causes nausea
by binding to certain (neurokinin 1) receptors in the brain. However, a modified version
of this treatment (AY = 0, AD = 1) can be created, where the chemical structure of the
old treatment is slightly changed such that it no longer binds to the receptors in the
brain (MaY =0,aD=1Y =M
a=0
Y ), but still exerts the cytotoxic effects on cancer cells and thus
reduces mortality (MaY =0,aD=1D = M
a=1
D ). Suppose that the new drug satisfies (4). Yet,
it does not necessarily satisfy the treatment decomposition assumption (5) because it is
not a (physical) decomposition of the old treatment.
Under (4), the conditional separable effect evaluated at AD = aD (3) is defined in
the subset of the population with DaY ,aDk+1 = D
a=aD
k+1 = 0, which is simply identified in
the current trial of Section 2 by those with DK+1 = 0 and treatment assignment A =
aD, aD ∈ {0, 1}.
Like AY partial isolation, assumption (4) for a choice of AY and AD must be justified
by subject matter knowledge, and can, in principle, be falsified in a plausible six arm
randomized experiment (denoted G′) in which individuals are randomly assigned to A
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(without assignment to AY or AD) or joint assignment to AY and AD (without assignment
to A). We can for example observe in this six arm trial whether E(V | AY = a, AD =
a) = E(V | A = a), for a = {0, 1} and V ∈ {Y,DK+1}, with failure of this equality
falsifying (4).
Causal graphs can display a necessary condition for the modified treatment assumption
(4); that is, whether A, AY and AD exert all their effects on Y and Dk+, k ∈ {0, K}
through MY and MD. This is illustrated in Figure 1d, which describes a 6 arm trial
G′ that expands the 2 arm-trial in Figure 1a. Furthermore, the graph in Figure 1b can
be interpreted as a transformation of the graph in Figure 1d that removes the node A,
representing the data generating mechanism under G′ had we removed the two arms
assigning A (i.e. a 4-arm trial G). It is not necessary to include MY and MD in this
reduced graph, because they are not common causes of any variable.
If we impose the treatment decomposition assumption of Robins and Richardson [10],
we can represent the causal structure in an extended causal DAG [10]; that is, a trans-
formation of the original causal DAG representing A and the components AY and AD,
where the mechanisms by which these components individually operate on outcomes are
encoded [10, 12]. For example, Figure 1c is an extension of Figure 1a representing (5),
with bold arrows representing deterministic relations. Under the decomposition assump-
tion, Figure 1b can be interpreted as a G-transformation of the extended DAG in Figure
1c, where (i) the node A (and any of its causes) are removed and (ii) all nodes are indexed
by G, with G again indexing the 4-arm trial discussed above.
6. AY partial isolation and meaningful effects of A on Y
By explicitly considering modified treatments such that AY partial isolation (2) and
the modified treatment assumption holds, the investigator is forced to articulate what she
means by an “effect of A on Y not through DK+1” under assumptions that are falsifiable
in a future experiment. This thought process requires the investigator to be explicit about
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her notion of a causal mechanism, and allows the consideration of a well-defined causal
effect: in particular, under these assumptions, the conditional separable effects quantify
mechanisms by which A affects Y that can be entirely separated from mechanisms by
which A affects Dk+1, k ∈ {0, K}. We discuss this further in Section 6.2.
If the investigator is unable to express a convincing story about modified treatments
satisfying (2) and the modified treatment assumption, then the relevance of an effect
of A on Y outside of its effect on the post-treatment event Dk+1 is ambiguous: the
investigator has failed to give a plausible scientific argument as to how effects of A on
Y can be disentangled from effects of A on Dk+1. Yet, even if the investigator cannot
define plausible modified treatments satisfying (2) and the modified treatment assumption
at this moment in time, these assumptions may be justified in the future: modified
treatments satisfying these assumptions might be revealed when more subject-matter
knowledge becomes available. However, until a plausible story can be articulated such
that (2) and the modified treatment assumption are satisfied, the practical relevance of
considering any effect of A on Y outside of its effect on Dk+1 – including the conventional
principal stratum effect – is unclear. In this case, the investigators must accept that they
do not understand how A exerts such effects and have no way to assess whether such
effects are operating in the data without reliance on assumptions that are impossible to
ever challenge in real-life experiments. In turn, without any ideas about such modified
treatments, we cannot imagine interventions to avoid or leverage effects of A on Y outside
of its effect on Dk+1.
6.1. Example: Cancer Treatment and Quality of Life. Returning to our cancer
treatment and quality of life example, suppose that Figure 2a represents data generating
assumptions on a trial that assigns treatment at baseline (A = 1 is new chemotherapy,
A = 0 is standard chemotherapy) with Y a quality of life measure at end of follow-up and
Dk+1 an indicator of death by time k+1. Suppose that there exist two modified treatments
AY and AD satisfying the following assumptions, which are also illustrated in Figure 2c:
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AD exerts effects on mortality Dk+1, k = 0, . . . , K, e.g. by destroying or reducing the
growth of cancer cells and thereby preventing cancer progression (Zj, j = 0, . . . , k+1). By
preventing cancer progression, the AD component may also reduce other health problems,
e.g. due to metastases, which affect quality of life Y (the path AD → Z → Y in Figure
2c). The other component AY does not exert effects on mortality, because it has little to
no activity against the cancer but may have side effects that adversely affect quality of
life; for example it may interfere with the replication of epithelial mucosal cells, resulting
in diarrhea and oral ulcers. Alternatively, this component may possibly have beneficial
effects (say due to a decrease in diarrhea and oral ulcers).
In this setting, the conditional separable effect evaluated at aD = 1 quantifies the treat-
ment effect on quality of life outside of its effect on disease progression. Specifically, this
quantifies the effect of assignment to a current chemotherapy (e.g. a = aY = aD = 1) ver-
sus a modified (hypothetical) therapy that contains the component of the current therapy
that reduces mortality and disease progression (aD = 1), but does not contain the compo-
nent that exerts effects on quality of life outside of mortality (aY = 0). An improvement
of quality of life under the modified therapy suggests that the new chemotherapy (a = 1)
contains a component that would be desirable to eliminate.
AY partial isolation would fail to hold in our example if AY exerts effects on a common
cause of Y and Dk+1, k = 0, . . . , K + 1, as illustrated in Figure 2d by the path AY →
Z1 → D2. One possible common cause could be quality of life at earlier times k < K. If
the AY component exerts effects on quality of life (which we now denote Zk for k < K)
only after a minimal latent period that extends beyond the study period [19], then AY
partial isolation may still be justified (e.g. the arrow from AY into Z1 in Figure 2d may be
removed). Alternatively, if quality of life only exerts effects on mortality after a minimal
latent period that extends beyond the study period then AY partial isolation may be
justified (e.g. the arrow from Z1 into D2 can be removed).
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6.2. When the conditional separable effect is the direct effect of A. While the
conditional separable effects are well-defined under AY partial isolation, this condition
allows additional causal paths from A to Y that are not intersected by Dk+1, k = 0, . . .K,
as illustrated in Figure 2c by the path AD → Z1 → Y . However, suppose that, in a causal
DAG representing the assumed data generating mechanism in the four-arm trial G,
the only causal paths from AD(G) to Y (G), are directed paths(6)
intersected by Dk(G), k = 1, ..., K,
which we refer to as AD partial isolation [12]. When both AD partial isolation (6) and
AY partial isolation (2) simultaneously hold, we say there is full isolation [12]. Under
full isolation, the conditional separable effects capture all causal paths from A to Y not
intersected by Dk+1, k = 0, . . .K. Full isolation is represented in Figures 1b and 2b.
Returning to our running cancer treatment and quality of life example represented by
Figure 2c, full isolation would hold under the stronger assumption that cancer progression
Zk, k = 0, . . . , K + 1 does not affect quality of life Y , allowing removal of the arrow from
Z1 to Y . This assumption seems to be implausible for many cancer treatments: by
preventing cancer progression, the treatment will not only reduce mortality, but also
reduce other effects of progression, such as pain related to tumor growth.
7. Identifiability conditions
If we had data from a four-arm trial in which AY and AD were randomly assigned
and censoring is absent, conditions required to identify E(Y aY ,aD | DaY ,aDK+1 = 0) for
aY , aD ∈ {0, 1} hold by design. Consequently, these conditions also identify the condi-
tional separable effects under the assumption of AY partial isolation by
(7) E(Y aY ,aD | DaDK+1 = 0) = E(Y
aY ,aD | DaY ,aDK+1 = 0).
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However, in the two-arm trial in which only the original treatment A is randomly assigned,
we are not guaranteed identification of E(Y aY ,aD | DaY ,aDK+1 = 0) when aY 6= aD in this
trial even when censoring is absent.
We now consider a set of conditions, beyond the conventional exchangeability, con-
sistency and positivity conditions that hold by design in the two-arm trial of Section
2 (reviewed in Appendix A, Theorem 1). Under AY partial isolation and the modified
treatment assumption, these conditions are sufficient to identify E(Y aY ,aD | DaY ,aDK+1 = 0)
when aY 6= aD using only data from this existing trial. By (7), this allows identification
of the conditional separable effects.
1. Positivity:
fLk,Dk+1(lk, 0) > 0 =⇒
Pr(A = a|Dk+1 = 0, Lk = lk) > 0, k ∈ {0, . . . , K}, a ∈ {0, 1}.(8)
Assumption (8) states that for any possibly observed level of the time-varying
covariate history among those surviving through each follow-up time, there exist
individuals with A = 1 and individuals with A = 0. Assumption (8) does not
hold by design in a randomized experiment, but it can be assessed in the observed
data.
2. Dismissible component conditions:
Y (G) ⊥ AD(G) | AY (G), DK+1(G) = 0, LK(G),(9)
Dk+1(G) ⊥ AY (G) | AD(G), Dk(G) = 0, Lk(G),(10)
Lk+1(G) ⊥ AY (G) | AD(G), Dk+1(G) = 0, Lk(G),(11)
for all k ∈ {0, . . . , K} where Y (G), Dk+1(G) and Lk+1(G) are values of the out-
come of interest, the conditioning event and the measured covariates at k+1 had
we implemented the four arm trial G that jointly assigns combinations of AY and
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AD. The dismissible component conditions can be assessed in G-transformation
graphs as discussed in Section 5; i.e. causal DAGs that represent the assumed
data generating mechanism in the future four arm trial G. For example Figure 4
depicts the assumption that there exist measured (e.g. L1) and unmeasured (e.g.
UL,Y or UL,D) common causes of Y and D2 in G. The dismissible component
conditions hold in Figures 4a-c, but (9) is violated in Figures 4d-e and (11) is
violated in Figure 4f.
Under these assumptions, we can identify the conditional counterfactual mean E(Y aY ,aD |
D
aY ,aD
K+1 = 0) by the following function of the observed data,∑
lK
E(Y | DK+1 = 0, LK = lK , A = aY )fL1,DK+1|L0,A(l1, 0 | l0, aD)fL0(l0)
P (DK+1 = 0 | A = aD)
.
(12)
See Appendix A (Theorem 1) for a proof that also covers settings where individuals can
be lost to follow-up2. We say that (12) is the g-formula for E(Y aY ,aD | DaY ,aDK+1 = 0) [2].
Importantly, AY partial isolation clarifies when a contrast of conditional counterfactual
outcome means,
E(Y aY ,aD=1 | DaY ,aD=1K+1 = 0) vs. E(Y
aY ,aD=0 | DaY ,aD=0K+1 = 0),
can be interpreted as a conditional causal effect: even if treatment AY is temporally
ordered before DK+1, AY partial isolation allows us to topologically order the component
AY after DK+1. That is, our estimands are isomorphic to estimands defined by interven-
tions where we first assign a treatment AD and then, after DK+1 occurs, we subsequently
assign AY . This can be seen on a SWIG with minimal labelling [16] consistent with AY
partial isolation, as in Figure 3a.
2In Appendix A. The proof for the identification formula of E(Y aY ,aD | DaY ,aDK+1 = 0) is given in a more
general setting where AY partial isolation is not required to hold. However, AY partial isolation is a
necessary condition for the conditional separable effects to be well-defined.
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7.1. Related works on identification of path specific effects. There is an intimate
link between identification results for our estimands and path-specific effects, as recently
discussed in Robins et al [18]: when there is no so-called recanting witness [20, 21] (see also
Stensrud et al [12, Section 6.5]), the (cross-world) counterfactuals defining a path specific
effect are equal to (single-world) counterfactuals defined by interventions on nodes in an
extended causal graph, like Figure 1c. Thus, the identification formulas for effects defined
by interventions in an extended causal graph are equal to identification formulas derived
for certain path-specific effects [18]. Malinsky et al [22] recently derived a complete
algorithm for identification of conditional path specific distributions [22], which is inspired
by the general identification theory of Shpitser [21]. However, while the identification
formulas for these estimands can be equal, the effects being identified are different: they
refer to interventions on different variables (see Robins et al [18] for a detailed discussion).
Unlike our current results, the previous works did not consider conditions under which
a contrast of conditional counterfactual outcome parameters can be interpreted as a
conditional causal effect (i.e. a contrast of counterfactual outcome means in the same set
of individuals).
7.2. New identification results for principal stratum effects. For the principal
stratum effect (1) to target the same subpopulation as the conditional separable effects
(3) under both aD = 0 and aD = 1, we must make the additional strong assumption that
Da=1k+1 = D
a=0
k+1, for k ∈ {0, K}. For example, under the assumption that lack of arrows in
a causal graph means no individual level causal effect, this requires that the arrow from
A into D1 in Figure 1a or the arrows from A into D1 and D2 in Figure 2a should be
removed. In our cancer and quality of life example, this assumption requires survival to
be identical under the new (a = 1) and standard (a = 0) chemotherapy. This underscores
that the conditional separable effects and the principal stratum effect (1) – specifically
the survivor average causal effect (SACE) in this example – are substantially different
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estimands; these estimands will only be equivalent in the restrictive setting where A
exerts no effect on mortality.
Suppose instead we make the weaker assumption that the effect of A on Dk+1 is mono-
tone: without loss of generality, this is the assumption that Da=1k+1 ≤ D
a=0
k+1 in all individu-
als for all k. Under this assumption, the principal stratum effect (1) is equivalent to the
conditional separable effect under aD = 0,
E(Y a=1 − Y a=0 | Da=1K+1 = D
a=0
K+1 = 0)
=E(Y a=1 − Y a=0 | Da=0K+1 = 0) by monotonicity
=E(Y aY =1,aD=1 | DaY =0,aD=0K+1 = 0)− E(Y
aY =0,aD=0 | DaY =0,aD=0K+1 = 0) by (4)
=E(Y aY =1,aD=0 | DaY =0,aD=0K+1 = 0)− E(Y
aY =0,aD=0 | DaY =0,aD=0K+1 = 0) by (2)
=E(Y aY =1,aD=0 − Y aY =0,aD=0 | DaY =0,aD=0K+1 = 0)
=E(Y aY =1,aD=0 − Y aY =0,aD=0 | DaD=0K+1 = 0) by (2).(13)
It follows directly from (13) that AY partial isolation and conditions (8)-(11) are suffi-
cient to identify the principal stratum effect (1) under monotonicity in the two-arm trial.
Thus, our identification results supplement the few suggested identifiability assumptions
that are sufficient for identification of principal stratum effects, such as the survivor av-
erage causal effect, in the presence of measured, possibly time-varying, common causes
of the event of interest and the post-treatment conditioning event [14, 17]. Furthermore,
except for monotonicity, we only rely on assumptions that can be falsified (rejected) in a
future randomized experiment.
8. Estimation
Let νaY ,aD denote the g-formula (12). Here we consider various estimators for this pa-
rameter in the absence of censoring. Extensions to allow censoring are given in Appendix
C.
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8.1. Outcome regression estimator. A simple outcome regression estimator νˆor,aY ,aD
of νaY ,aD is the solution to the estimating equation
∑n
i=1 Uor,i(νaY ,aD , θˆ) = 0 with respect
to νaY ,aD , with
Uor,i(νaY ,aD , θˆ) = I(Ai = aD)(1−Dk+1,i)
(
E(Y | DK+1 = 0, A = aY , LK ; θˆ)− νaY ,aD
)
,
where E(Y | DK+1 = 0, A = aY , LK ; θ) is a parametric model for E(Y | DK+1 =
0, LK , A = aY ) indexed by the parameter θ and assume θˆ is its MLE. The estimating
equation Uor,i(νaY ,aD , θˆ) has mean zero and the estimator νˆor,aY ,aD is consistent provided
that this model is correctly specified.
8.2. Weighted estimator. Alternatively, define the weighted estimator νˆipw,aY ,aD of
νaY ,aD as the solution to the estimating equation
∑n
i=1 Uipw,i(νaY ,aD , αˆ) = 0 with respect
to νaY ,aD , with
Uipw,i(νaY ,aD , αˆ) = I(Ai = aY )(1−Dk+1,i)Wˆi(aY , aD; αˆ) (Yi − νaY ,aD) ,
such that
Wˆ (aY , aD; αˆ) =
fL1,DK+1|L0,A(L1, 0 | L0, aD; αˆ)
fL1,DK+1|L0,A(L1, 0 | L0, aY ; αˆ)
is an estimator of
W (aY , aD) =
fL1,DK+1|L0,A
(L1, 0 | L0, A = aD)
fL1,DK+1|L0,A(L1, 0 | L0, A = aY )
,(14)
where fL1,DK+1|L0,A(L1, 0 | L0, A = a;α) is a parametric model for fL1,DK+1|L0,A(L1, 0 |
L0, A = a) indexed by the parameter α and assume αˆ is its MLE. If this model is
correctly specified, then νˆipw,aY ,aD is a consistent estimator for νaY ,aD , which follows from
an alternative representation of the g-formula that is derived in Appendix A.1 (Theorem
2).
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In practice, parameterizing the terms in W (aY , aD) requires care when LK is high-
dimensional. However, we can re-express Wˆ (·) as a product of the terms
WˆD(aY , aD; αˆD) =
∏K
j=0Pr(Dj+1 = 0 | Lj, Dj = 0, A = aD; αˆD)∏K
j=0Pr(Dj+1 = 0 | Lj , Dj = 0, A = aY ; αˆD)
,
WˆL(aY , aD; αˆL) =
∏K−1
j=0 fLj+1|Dj+1,Lj ,A(Lj+1 | 0, Lj , aD; αˆL)∏K−1
j=0 fLj+1|Dj+1,Lj ,A(Lj+1 | 0, Lj , aY ; αˆL)
,
where Pr(Dj+1 = 0 | Dj = 0, Lj , A = a;αD) is a pooled over time model for Pr(Dj+1 =
0 | Dj = 0, Lj , A = a) indexed by the parameter αD, and αˆD its MLE. The pa-
rameter αL analogously indexes a pooled over time model for the conditional density
fLj+1|Dj+1,Lj ,A(Lj+1 | 0, Lj , a), with αˆL its MLE. Off the shelf software can be used to esti-
mate Pr(Dj+1 = 0 | Dj = 0, Lj, A = a). More complex computation (and strong paramet-
ric assumptions) may be required to consistently estimate fLj+1|Dj+1,Lj ,A(Lj+1 | 0, Lj , a)
when Lj is high-dimensional. In this case, we can alternatively fit a model directly for
the likelihood ratio
fLj+1|Dj+1,Lj ,A(Lj+1 | 0, Lj, aD)
fLj+1|Dj+1,Lj ,A(Lj+1 | 0, Lj , aY )
j ∈ {0, K}, e.g. a proportional likelihood ratio model as a more parsimonious function
of Lj and possibly j which avoids distributional assumptions on Lj+1 [23].
8.3. Doubly robust estimator. We can alternatively consider a doubly robust estima-
tor derived from the nonparametric influence function in Appendix B [24, 25, 26]. This
estimator νˆdr,aY ,aD is the solution to the estimating equation
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Udr(νaY ,aD , αˆ, θˆ) =
1
Eˆ(1−DK+1 | A = aD)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)E(Y | DK+1 = 0, A = aY , LK ; θˆ)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A
(L1, 0 | L0, aD); αˆ)
fL1,DK+1|L0,A(L1, 0 | L0, aY ; αˆ)
(1−DK+1)
×[Y − E(Y | DK+1 = 0, A = aY , LK)]
}
−νaY ,aD ,
with Eˆ(1−DK+1 | A = aD) simply a sample mean. In Appendix B we show that νˆdr,aY ,aD is
doubly robust; that is, it is consistent if either the models for fL1,DK+1|L0,A(L1, 0 | L0, a) or
E(Y | DK+1 = 0, LK , A = a) are correctly specified, but not necessarily both. Analogous
to the weighted estimator νˆIPW,aY ,aD , consistency of νˆdr,aY ,aD may also be acheived by
correctly specifying a model for the likelihood ratio in place of fL1,DK+1|L0,A(L1, 0 | L0, a),
as described in the previous section. Note that the estimating equation for νˆdr,aY ,aD
can serve as the basis for constructing estimators that use machine learning to estimate
nuisance parameters in place of parametric models.
9. Data example: the Southwest Oncology Group Trial.
As an illustration, we analyzed data from the Southwest Oncology Group (SWOG)
Trial [27] that randomly assigned men with refractory prostate cancer to either of two
chemotherapies, Docetaxel and Estramustine (DE) or Mitoxantrone and Prednisone (MP).
Our dataset, which included 487 patients aged 47 to 88 years, has previously been used to
compare outcomes under DE versus MP on health related quality of life in the principal
stratum of always survivors [17, 28, 29], that is, to estimate the survivor average causal
effect. Yet, the practical relevance of the survivor average causal effect is ambiguous, as
we discussed in Section 6.
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The conditional separable effects quantify notions of causal mechanisms and can be
used to conceive improved treatments. Thus, our target of inference was a conditional
separable effect of DE versus MP on the outcome Y , defined as the change in quality of life
between baseline and one year of follow-up, similar to the previous reports evaluating the
SACE [17, 28, 29]. We considered a modification of the original treatments DE (A = 1)
and MP (A = 0), where AD = 1 indicates receiving only the Docetaxel component of DE
and AD = 0 indicates receiving only Mitoxantrone component of MP. Both Docetaxel and
Mitoxantrone are chemotherapeutic agents that can reduce proliferation of cancer cells,
and, potentially, progression of the disease (Zk). Further, let AY = 1 indicate receiving
only Estramustine component of DE (AY = 1) and AY = 0 indicate receiving only the
Prednisone component of MP. Assume that AY partial isolation is satisfied. Clearly, this
condition is not guaranteed by design, but may be plausible for these choices of AY and
AD. Specifically, neither Estramustine, which consists of estrogen and chemotherapeutic
medication, nor Prednisone, a steroid, are given to reduce mortality. However, these
components can potentially give pain relief (palliation) [30], but may also have side-
effects, including nausea, fatigue and vomiting [31, 27, 30], which in turn can affect
quality of life. Therefore, it is not clear which of these components are most effective at
improving quality of life.
The causal structure of this example is represented in Figure 2c, satisfying AY partial
isolation, where the causal path AD → Z1 → Y illustrates that AD can also affect quality
of life through its effect on cancer progression.
After K + 1 = 12 months of follow-up, 0.79 (95% CI: [0.73, 0.84]) survived in the DE
arm compared to 0.72 (95% CI: [0.66, 0.78]) in the MP arm, resulting in an estimated
additive causal effect of 0.07 (95% CI: [−0.01, 0.15]) of treatment A on 12-month survival
(D12). Of the 368 survivors at 12 months, 152 had a measure of the outcome quality
of life measured (i.e. were uncensored). All analyses were adjusted for the measured
baseline covariates age, race, anticipated of prognosis, bone pain and performance status
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(L0) as well as an indicator of disease progression by k (Lk). These point estimates are
in line with a possible improvement in mortality under DE compared to PM. By our
hypotheses above, this suggests that the effect of a modified version of DE that replaces
the Estramustine component with Prednisone (i.e. the joint treatment AD = 1, AY = 0)
is of interest with respect to quality of life.
The estimated mean of Y among survivors was -4.4 (95% CI: [−8.6,−0.5]) units in
the DE arm (aD = aY = 1) and -9.1 (95% CI: [−14.0,−3.9]) units in the ME arm
(aD = aY = 0) (Table 1). However, we cannot assign a causal interpretation to a
contrast of these estimates, as discussed in Section 1. Therefore we estimated the condi-
tional separable effect for aD = 1 (i.e. the comparison of outcomes under Estramustine
versus Prednisone both given with Docetaxel) using the regression estimator νˆor,aY ,aD , the
weighted estimator νˆipw,aY ,aD based on the weights Wˆ (aY , aD; αˆ) as well as the doubly-
robust estimator νˆdr,aY ,aD . We assumed the following parametric models for the nuisance
parameter fL1,DK+1|L0,A(L1, 0 | L0, aD),
logit[Pr(D12 = 1 | A = 0, L0, L11;αD1)] = αD,0 + α
′
D,1L0 + αD,2L11,
logit[Pr(D12 = 1 | A = 1, L0, L11;αD2)] = αD,3 + α
′
D,4L0 + αD,5L11,
logit[Pr(L11 = 1 | A,L0;αL)] = αL,0 + αL,1A+ α
′
L,2L0,
and the following model for E(Y | D12 = 0, A = aY , L11 = l11),
E(Y | DK+1 = 0, A = a, LK = lK ; θ) = θ0 + θ1A+ θ
′
2L0 ++θ3L11.
Under the hypothetical treatment that contains the component of DE that affects
mortality (Docetaxel, aD = 1), but contains the component of MP that potentially affects
quality of life outside of mortality (Prednisone, aY = 0), the estimated mean outcome
after 12 months was −6.1 (95% CI [−11.8,−0.7]) using the simple regression estimator
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νˆor,aY ,aD (Table 1). The estimated additive conditional separable effect for aD = 1 was
equal to −1.7 (95% CI [−5.1, 8.1]).
Similarly, using the simple weighted estimator νˆipw,aY ,aD the estimated mean outcome
after 12 months was −5.5 (95% CI [−9.7,−0.4]) (Table 1), and the estimated additive
conditional separable effect for aD = 1 was equal to −1.1 (95% CI [−5.6, 6.6]). We also
implemented the doubly robust estimator νˆdr,aY ,aD , which gave an estimated outcome
mean of −5.6 (95% CI [−11.5,−0.2]) (Table 1), and an estimated conditional separable
effect for aD = 1 equal to −1.7 (95% CI [−5.1, 8.4]). Thus, the estimates from νˆor,aY ,aD ,
νˆipw,aY ,aD and νˆdr,aY ,aD are similar. The confidence intervals are wide, and there is no clear
evidence that the modified drug with Docetaxel and Prednisone would lead to improved
quality of life compared to DE in this study. These conclusions, however, rely on the
assumption of AY partial isolation and the identifiability conditions in Section 7. In
particular, the presence of unmeasured common causes of mortality and quality of life
would violate these assumptions.
As discussed in Section 7.2, under the additional assumption of monotonicity, our
results also allow identification and estimation of the SACE. However, we have already
argued that the practical relevance of the SACE is ambiguous. Under the additional
assumption of a monotonic effect of aD on mortality, i.e. D
aD=1
12 ≤ D
aD=0
12 , the SACE is
identified by the same functional as the conditional separable effect where aD is fixed to
0,
E(Y aY =0,aD=0 | DaY =0,aD=012 = 0)− E(Y
aY =1,aD=0 | DaY =1,aD=012 = 0),
that is, the conditional separable effect among those who would survive under Mitox-
antrone, regardless of whether they received Prenisone or Estramustine. In contrast, we
have argued that the separable effect among those who would survive under Docetaxel
(where aD is fixed to 1) is of primary interest. Furthermore, we do not believe that
monotonicity holds in our example, i.e. that Mitoxantrone does not improve survival in
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any single individual: different individuals can experience different effects of Docetaxel
and Mitoxantrone on survival, e.g. due to differences in the cancer cells (subtypes) across
individuals.
The only form of censoring in this data set was due to missing values of Y . In Appendix
C, we describe how censoring was adjusted for in the analysis.
10. Discussion
This work presents new estimands, conditional separable effects, in settings where
the outcome of interest is only defined conditional on a post-treatment event status.
To define the conditional separable effects, we relied on the assumption of AY partial
isolation and the existence of two modified treatments that exert effects through distinct
causal pathways [10, 11, 12, 32].
Principal stratum effects have often been used to quantify causal effects on an outcome
that is only of interest conditional on a post-treatment variable, such as survival [2,
3] or having an infection [33], but the practical relevance of these estimands has been
questioned, because (i) they are defined in an unknown subpopulation that may not even
exist [7, 8, 34], and (ii) estimating the principal stratum effects requires unfalsifiable
assumptions that cannot be verified even in any randomized experiment [10].
Unlike principal stratum effects, the conditional separable effects can be identified
without relying on unfalsifiable independence assumptions or hypothetical interventions
to prevent death; the conditional separable effects can be identified in a Finest Fully
Randomized Causally Interpreted Structured Tree Graph (FFRCISTG) model [2, 10, 16].
As such, the identifiability conditions can be scrutinized in a future experiment in which
the treatment components AY and AD are randomly assigned. Unlike principal stratum
effects, the conditional separable effects are not restricted to an unknown subpopulation
of unknown size, but the two versions of the conditional separable effects (evaluated under
either aD = 0 or aD = 1) are defined in the (observable) subsets of individuals who would
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have a particular value of a post-treatment variable under assignment A = 0 and A = 1,
respectively.
Thus, the conditional separable effects overcome key concerns with principal stratum
estimands, such as the survivor average causal effects. Yet the definition of the condi-
tional separable effects hinges on AY partial isolation, which must be justified in each
practical setting. However, this is not a limitation of the estimand itself: unless we con-
ceive plausible modified treatments meeting AY partial isolation, it is not clear how to
disentangle treatment effects on the post-treatment variable (e.g. death) and treatment
effects on the outcome of interest. Furthermore, our results help researchers clarify their
thinking about future, potentially improved treatments. The study of these future treat-
ments is of scientific and public health interest, even if AY partial isolation is falsified in
a future experiment evaluating these treatments.
28
References
[1] James M Robins and Sander Greenland. Identifiability and exchangeability for direct and indirect
effects. Epidemiology, pages 143–155, 1992.
[2] James M Robins. A new approach to causal inference in mortality studies with a sustained exposure
period—application to control of the healthy worker survivor effect. Mathematical modelling, 7(9-
12):1393–1512, 1986.
[3] Constantine E Frangakis and Donald B Rubin. Principal stratification in causal inference. Biomet-
rics, 58(1):21–29, 2002.
[4] Peng Ding and Jiannan Lu. Principal stratification analysis using principal scores. Journal of the
Royal Statistical Society: Series B (Statistical Methodology), 79(3):757–777, 2017.
[5] Tyler J VanderWeele. Principal stratification–uses and limitations. The international journal of
biostatistics, 7(1):1–14, 2011.
[6] Donald B Rubin et al. Causal inference through potential outcomes and principal stratification:
application to studies with “censoring” due to death. Statistical Science, 21(3):299–309, 2006.
[7] James M Robins, Andrea Rotnitzky, and Stijn Vansteelandt. Principal stratification designs to
estimate input data missing due to death-discussion. Biometrics, 63(3):650–653, 2007.
[8] Marshall Joffe. Principal stratification and attribution prohibition: good ideas taken too far. The
international journal of biostatistics, 7(1):1–22, 2011.
[9] Philip Dawid and Vanessa Didelez. “ imagine a can opener”–the magic of principal stratum analysis.
The international journal of biostatistics, 8(1), 2012.
[10] James M Robins and Thomas S Richardson. Alternative graphical causal models and the identifi-
cation of direct effects. Causality and psychopathology: Finding the determinants of disorders and
their cures, pages 103–158, 2010.
[11] Mats J. Stensrud, Jessica G. Young, Vanessa Didelez, James M. Robins, and Miguel A. Herna´n.
Separable Effects for Causal Inference in the Presence of Competing Risks. arXiv e-prints, page
arXiv:1901.09472, January 2019.
[12] Mats J. Stensrud, Eric Tchetgen Tchetgen, Vanessa Didelez, James M. Robins, Miguel A Herna´n,
and Jessica G. Young. Generalized interpretation and identification of separable effects in competing
event settings. Forthcoming, 2019.
[13] Douglas Hayden, Donna K Pauler, and David Schoenfeld. An estimator for treatment comparisons
among survivors in randomized trials. Biometrics, 61(1):305–310, 2005.
29
[14] Eric J Tchetgen Tchetgen. Identification and estimation of survivor average causal effects. Statistics
in medicine, 33(21):3601–3628, 2014.
[15] Judea Pearl. Causality: Models, Reasoning and Inference 2nd Edition. Cambridge University Press,
2000.
[16] Thomas S Richardson and James M Robins. Single world intervention graphs (swigs): A unification
of the counterfactual and graphical approaches to causality. Center for the Statistics and the Social
Sciences, University of Washington Series. Working Paper, 128(30):2013, 2013.
[17] Linbo Wang, Xiao-Hua Zhou, and Thomas S Richardson. Identification and estimation of causal
effects with outcomes truncated by death. Biometrika, 104(3):597–612, 2017.
[18] James M Robins, Thomas S Richardson, and Ilya Shpitser. An interventionist approach to mediation
analysis. Forthcoming, 2020.
[19] James M Robins. Causal models for estimating the effects of weight gain on mortality. International
Journal of Obesity, 32(3):S15–S41, 2008.
[20] Chen Avin, Ilya Shpitser, and Judea Pearl. Identifiability of path-specific effects. Proceedings of
International Joint Conference on Artificial Intelligence, 2005.
[21] Ilya Shpitser. Counterfactual graphical models for longitudinal mediation analysis with unobserved
confounding. Cognitive science, 37(6):1011–1035, 2013.
[22] Daniel Malinsky, Ilya Shpitser, and Thomas Richardson. A potential outcomes calculus for identi-
fying conditional path-specific effects. Proceedings of machine learning research, 89:3080, 2019.
[23] Xiaodong Luo and Wei Yann Tsai. A proportional likelihood ratio model. Biometrika, 99(1):211–222,
2012.
[24] James M Robins, Andrea Rotnitzky, and Lue Ping Zhao. Estimation of regression coefficients
when some regressors are not always observed. Journal of the American statistical Association,
89(427):846–866, 1994.
[25] Mark J Van der Laan, MJ Laan, and James M Robins. Unified methods for censored longitudinal
data and causality. Springer Science & Business Media, 2003.
[26] Aad W Van der Vaart. Asymptotic statistics, volume 3. Cambridge university press, 2000.
[27] Daniel P Petrylak, Catherine M Tangen, Maha HA Hussain, Primo N Lara Jr, Jeffrey A Jones,
Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli, et al. Docetaxel
and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate
cancer. New England Journal of Medicine, 351(15):1513–1520, 2004.
30
[28] Peng Ding, Zhi Geng, Wei Yan, and Xiao-Hua Zhou. Identifiability and estimation of causal effects
by principal stratification with outcomes truncated by death. Journal of the American Statistical
Association, 106(496):1578–1591, 2011.
[29] Fan Yang and Peng Ding. Using survival information in truncation by death problems without the
monotonicity assumption. Biometrics, 74(4):1232–1239, 2018.
[30] Daniel P Petrylak. Future directions in the treatment of androgen-independent prostate cancer.
Urology, 65(6):8–12, 2005.
[31] Karen A Autio, Howard I Scher, and Michael J Morris. Therapeutic strategies for bone metastases
and their clinical sequelae in prostate cancer. Current treatment options in oncology, 13(2):174–188,
2012.
[32] Vanessa Didelez. Defining causal meditation with a longitudinal mediator and a survival outcome.
Lifetime data analysis, pages 1–18, 2018.
[33] Michael G Hudgens, Antje Hoering, and Steven G Self. On the analysis of viral load endpoints in
hiv vaccine trials. Statistics in medicine, 22(14):2281–2298, 2003.
[34] Jessica G. Young, Mats J. Stensrud, Eric J. Tchetgen Tchetgen, and Miguel A. Herna´n. A causal
framework for classical statistical estimands in failure-time settings with competing events. Statistics
in Medicine, 39(8):1199–1236, 2020.
[35] Peter J Bickel, Chris AJ Klaassen, Peter J Bickel, and Yaacov Ritov. Efficient and adaptive estima-
tion for semiparametric models, volume 4. Johns Hopkins University Press Baltimore, 1993.
[36] Edward H Kennedy. Semiparametric theory and empirical processes in causal inference. In Statistical
causal inferences and their applications in public health research, pages 141–167. Springer, 2016.
[37] Aad W van der Vaart. Semiparametric statistics. Lecture Notes in Math., 2002.
[38] Anastasios Tsiatis. Semiparametric theory and missing data. Springer Science & Business Media,
2007.
31
Estimand Estimator Estimate (95% CI)
E(Y a=1 | Da=112 = 0) Non-parametric -4.4 (-8.6, -0.5)
E(Y a=0 | Da=012 = 0) Non-parametric -9.1 (-14.0, -3.9)
E(Y aY =0,aD=1 | DaY =0,aD=112 = 0) νˆor,aY ,aD -6.1 (-11.8, -0.7)
E(Y aY =0,aD=1 | DaY =0,aD=112 = 0) νˆipw,aY ,aD -5.5 (-9.7, -0.4)
E(Y aY =0,aD=1 | DaY =0,aD=112 = 0) νˆdr,,aY ,aD -5.6 (-11.5, -0.2)
Table 1. Estimates of changes in health related quality of life 12 months
after baseline. The percentile based confidence intervals are derived from
500 bootstrap samples.
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(d)
Figure 1. The DAG in (a) is a simple causal DAG allowing no common
cause of the outcome of interest (Y ) and D1. The DAG in (b) represents a
four-arm trial G assigning two treatments AY and AD consistent with AY
partial isolation. The graph in (c) is consistent with the modified treatment
assumption for this choice of AY and AD via the treatment decomposition
assumption (5) from Robins and Richardson [10], where the bold arrows
describe the deterministic relation between A, AY andAD. The graph in (d)
describes a necessary condition for the the modified treatment assumption.
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A D1 D2 Y
Z1Z0
(a)
AY
AD
D1 D2 Y
Z1Z0
(b)
AY
AD
D1 D2 Y
Z1Z0
(c)
AY
AD
D1 D2 Y
Z1Z0
(d)
Figure 2. The graph in (a) is a classical DAG with no assumption about
modified treatments. The graphs in (b)-(d) are DAGs describing four-arm
trials, i.e. “G”s, that illustrate the (mechanistic) isolation assumptions for
modified treatments AY and AD, where we have omitted (G) in each node
to avoid clutter. Full isolation holds in (b), only AY partial isolation holds
in (c) and only AD partial isolation holds in (d).
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AY aY
AD aD
D
aD
1 D
aD
2 Y
aY ,aD
Z
aD
1Z0
(a)
AY aY
AD aD
D
aD
1 D
aY ,aD
2 Y
aY ,aD
Z
aY ,aD
1Z0
(b)
Figure 3. Single World Intervention Graphs (SWIGs). The SWIG in (a)
is a transformation of the causal DAG in Figure 2c under an intervention
aY , aD, where AY partial isolation holds. The SWIG in (b) is a corre-
sponding transformation of the causal DAG in Figure 2d, where AY partial
isolation fails. Unlike in the graph (a), we cannot remove aY from the
superscripts of ZaY ,aD1 D
aY ,aD
2 in (b) by minimal labelling [16].
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AY
AD
D1 D2 Y
L1UL,D
(a)
AY
AD
D1 D2 Y
L1 UL,Y
(b)
AY
AD
D1 D2 Y
L1UL,D
(c)
AY
AD
D1 D2 Y
L1 UL,Y
(d)
AY
AD
D1 D2 Y
L1 UL,YUL,D
(e)
AY
AD
D1 D2 Y
L1
(f)
Figure 4. The dismissible component conditions can be studied in causal
graphs. Similar to Figure 2, we have omitted the string (G) in each node
to avoid clutter. In (a)-(c), the dismissible component conditions hold. In
(d)-(e), dismissible component condition (9) is violated. In (f), dismissible
component condition (11) is violated.
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Appendix A. Proof of identification formula
Here we provide a proof for the identification formula of E(Y aY ,aD | DaY ,aDK+1 = 0), which
is sufficient for identification of the conditional separable effects in settings with loss to
follow-up (censoring). This identification formula co-incide with the identification formula
in Malinsky et al [22] for path specific effects (See also Robins et al [18]). Denote Ck+1 an
indicator of censoring by k+1, C0 ≡ 0 and assume topological ordering (Ck+1, Dk+1, Lk+1)
in each k = 0, . . . , K. Consider the following more general exchangeability, consistency
and positivity conditions which coincide with those given in Section 7 of the main text
when loss to follow-up is absent. For each a ∈ {0, 1}:
1. Exchangeability:
Y a,c=0, D
a,c=0
1 , L
a,c=0
1 ⊥ A | L0(15)
Y a,c=0, D
a,c=0
k+1 , L
a,c=0
k+1 ⊥ Ck+1 | Dk = Ck = 0, Lk, A.(16)
Condition (15) holds if A is randomly assigned at baseline, possibly conditional
on L0. Condition (16) states that losses to follow-up are independent of future
counterfactual events, conditional on the measured past. This assumption does
not hold by design in a trial where A is randomly assigned, because losses to
follow-up are not randomly assigned in practice.
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2. Positivity:
fL0(l0) > 0 =⇒
Pr(A = a | L0 = l0) > 0,(17)
fLk,Ck+1,Dk+1(lk, 0, 0) 6= 0 for a ∈ {0, 1} =⇒
Pr(A = a|Dk+1 = 0, Ck+1 = 0, Lk = lk) > 0(18)
f(A = a,Dk = 0, Ck = 0, Lk = lk) > 0 =⇒
Pr(Ck+1 = 0 | Dk = 0, Ck = 0, Lk = lk, A = a) > 0.(19)
Here, (17) and (18) are analogous to the conditions in the main text. Condition
(19) ensures that for any possible history of treatment assignments and covariates
among those who are event-free and uncensored at k, some individuals will remain
uncensored at k + 1. Condition (19) is only required when loss to follow-up is
present.
3. Consistency:
if A = a and Ck+1 = 0,
then Y = Y
a,c=0
, Dk+1 = D
a,c=0
k+1 and Lk+1 = L
a,c=0
k+1 .(20)
Consistency is satisfied any individual who has data history consistent with the
intervention under a counterfactual scenario, would have an observed outcome
that is equal to the counterfactual outcome.
Also consider the following more general version of the dismissible component
conditions where (LAY ,k+1, LAD,k+1) is some partition of Lk+1:
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4. Dismissible component conditions:
Y (G) ⊥ AD(G) | AY (G), DK+1(G) = 0, LK(G),(21)
Dk+1(G) ⊥ AY (G) | AD(G), Dk(G) = 0, Lk(G),(22)
LAY ,k+1(G) ⊥ AD(G) | AY (G), Dk+1(G) = 0, Lk(G), LAD,k+1(G),(23)
LAD ,k+1(G) ⊥ AY (G) | AD(G), Dk+1(G) = 0.Lk(G)(24)
Following Appendix C of [12], these dismissible component conditions and AY
partial isolation give the dismissible component conditions of Section 7 in the
main text; conditions (9)-(11) are equivalent to (22)-(24) under the partition
LAY ,k+1 = Lk+1 and LAD ,k+1 = ∅ .
Theorem 1. Under the modified treatment assumption, if conditions (15)-(24) hold,
E(Y aY ,aD ,c=0 | DaY ,aD,c=0K+1 = 0) is identified by
E(Y aY ,aD,c=0 | DaY ,aD ,c=0K+1 = 0)
=
∑
lK
E(Y | DK+1 = CK+1 = 0, LK = lK , A = aY )
K∏
s=0
[
Pr(Ds+1 = 0 | ls, Ds = Cs+1 = 0, A = aD)
× Pr(LAY ,s = lAY ,s | lAD,s, ls−1, Ds = Cs = 0, A = aY )
× Pr(LAD ,s = lAD,s | ls−1, Ds = Cs = 0, A = aD)
]
×
[∑
lk
K∏
s=0
Pr(Ds+1 = 0 | ls, Ds = Cs = 0, A = aD)
× Pr(LAY ,s = lAY ,s | lAD,s, ls−1, Ds = Cs = 0, A = aY )
× Pr(LAD ,s = lAD,s | ls−1, Ds = Cs = 0, A = aD)
]−1
,(25)
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which reduces to the identification formula (12) when AY partial isolation holds, there is
no censoring and A ⊥ L0.
Proof. Assume that conditions (15)-(24) hold. Using laws of probability,
E(Y aY ,aD ,c=0 | DaY ,aD,c=0K+1 = 0)
=
∑
lK
E(Y aY ,aD ,c=0 | DaY ,aD,c=0K+1 = 0, L
aY ,aD,c=0
K = lK) Pr(L
aY ,aD ,c=0
K = lK | D
aY ,aD,c=0
K+1 = 0)
=
∑
lK
E(Y aY ,aD ,c=0 | DaY ,aD,c=0K+1 = 0, L
aY ,aD,c=0
K = lK)
Pr(L
aY ,aD,c=0
K = lK , D
aY ,aD,c=0
K+1 = 0)
Pr(DaY ,aD ,c=0K+1 = 0)
=
∑
lK
E(Y aY ,aD,c=0 | DaY ,aD ,c=0K+1 = 0, L
aY ,aD ,c=0
K = lK) Pr(L
aY ,aD,c=0
K = lK , D
aY ,aD,c=0
K+1 = 0)
Pr(DaY ,aD ,c=0K+1 = 0)
(26)
Our task now remains to express each term in (26) as a function of observed data un-
der the stated identifying conditions above. We begin with the term Pr(L
aY ,aD ,c=0
K =
lK , D
aY ,aD,c=0
K+1 = 0). By probability laws and a partitioning Lk+1 = (LAY ,k+1, LAD,k+1),
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k = 0, . . . , K, we have:
Pr(L
aY ,aD,c=0
K = lK , D
aY ,aD,c=0
K+1 = 0)
=Pr(DaY ,aD ,c=0K+1 = 0 | L
aY ,aD ,c=0
K = lK , D
aY ,aD ,c=0
K = 0)
× Pr(LaY ,aD ,c=0AY ,K = lAY ,K | D
aY ,aD,c=0
K = 0, L
aY ,aD,c=0
K−1 = lK−1, L
aY ,aDc=0
AD,K
= lAD ,K)
× Pr(LaY ,aD ,c=0AD ,K = lAD ,K | D
aY ,aD ,c=0
K = 0, L
aY ,aD ,c=0
K−1 = lK−1)
× Pr(DaY ,aD ,c=0K = 0, L
aY ,aD ,c=0
K−1 = lk−1)
Arguing iteratively:
=
K∏
s=0
Pr(DaY ,aD ,c=0s+1 = 0 | L
aY ,aD ,c=0
s = ls, D
aY ,aD,c=0
s = 0)
× Pr(LaY ,aD ,c=0AY ,s = l
aY ,aD ,c=0
AY ,s
| DaY ,aD,c=0s = 0, L
aY ,aD,c=0
s−1 = l
aY ,aD,c=0
s−1 , L
aY ,aD,c=0
AD,s
= lAD,s)
× Pr(LaY ,aD ,c=0AD ,s = lAD ,s | D
aY ,aD,c=0
s = 0, L
aY ,aD ,c=0
s−1 = ls−1)
Using the dismissible component conditions∗ and the modified treatment assumption∗∗:
=
K∏
s=0
Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls, D
a=aD,c=0
s = 0)
× Pr(La=aY ,c=0AY ,s = lAY ,s | D
a=aY ,c=0
s = 0, L
a=aY ,c=0
s−1 = ls−1, L
a=aY ,c=0
AD,s
= lAD,s)
× Pr(La=aD ,c=0AD ,s = lAD ,s | D
a=aD ,c=0
s = 0, L
a=aD ,c=0
s−1 = ls−1).
(27)
Remark on last equality
* The dismissible component conditions, which are defined as independencies, imply the
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following equalities of conditional hazards (See Lemma 1, in Stensrud et al [12]),
Pr(Y aY ,aD=0,c¯=0 = 1 | DaY ,aD=0,c¯=0k+1 = 0, L¯
aY ,aD=0,c¯=0
k = l¯k)
=Pr(Y aY ,aD=1,c¯=0 = 1 | DaY ,aD=1,c¯=0k+1 = 0, L¯
aY ,aD=1,c¯=0
k = l¯k),
Pr(DaY =0,aD ,c¯=0k+1 = 1 | D
aY =0,aD ,c¯=0
k = 0, L¯
aY =0,aD ,c¯=0
k = l¯k)
=Pr(DaY =1,aD ,c¯=0k+1 = 1 | D
aY =1,aD ,c¯=0
k = 0, L¯
aY =1,aD ,c¯=0
k = l¯k),
Pr(LaY ,aD=1,c¯=0AY ,k+1 = l
aY ,aD=1,c¯=0
AY ,k+1
| DaY ,aD=1,c¯=0k+1 = 0, L¯
aY ,aD=1,c¯=0
k = l¯k, L
aY ,aD=1,c¯=0
AD ,k+1
= lAD ,k+1)
=Pr(LaY ,aD=0,c¯=0AY ,k+1 = l
aY ,aD=0,c¯=0
AY ,k+1
| DaY ,aD=0,c¯=0k+1 = 0, L¯
aY ,aD=0,c¯=0
k = l¯k, L
aY ,aD=0,c¯=0
AD ,k+1
= lAD ,k+1),
Pr(LaY =0,aD ,c¯=0AD,k+1 = l
aY =0,aD ,c¯=0
AD ,k+1
| DaY =0,aD ,c¯=0k+1 = 0, L¯
aY =0,aD ,c¯=0
k = l¯k)
=Pr(LaY =1,aD ,c¯=0AD,k+1 = l
aY =1,aD ,c¯=0
AD ,k+1
| DaY =1,aD ,c¯=0k+1 = 0, L¯
aY =1,aD ,c¯=0
k = l¯k).
∗∗ Note that the modified treatment assumption is defined with respect to Zs, not Ls.
Thus, we can only apply this condition to Ls such that Ls ⊂ Zk. Clearly, it is practically
sensible to select Ls such that Ls ⊂ Zk. However, suppose that the investigator selected
Ls such that L
′
s ⊂ Ls and L
′
s 6⊂ Zs and the dismissible component conditions hold. Then,
the last equality still holds because, by definition of Zs, L
′
s does not exert effects on either
Y or Dk, so it can be removed (and re-included) from all the conditioning sets.
End of Remark.
Next consider the term Pr(DaY ,aD,c=0K+1 = 0) in the denominator of (26). Invoking proba-
bility rules, the dismissible component conditions and the modified treatment assumption,
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we have:
Pr(DaY ,aD,c=0K+1 = 0)
=
∑
lK
K∏
s=0
Pr(DaY ,aD ,c=0s+1 = 0 | L
aY ,aD ,c=0
s = ls, D
aY ,aD,c=0
s = 0)
× Pr(LaY ,aD ,c=0AY ,s = lAY ,s | D
aY ,aD,c=0
s = 0, L
aY ,aD,c=0
s−1 = ls−1, L
aY ,aD,c=0
AD,s
= lAD ,s)
× Pr(LaY ,aD ,c=0AD ,s = lAD,s | D
aY ,aD,c=0
s = 0, L
aY ,aD,c=0
s−1 = ls−1)
=
∑
lK
K∏
s=0
Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls = ls, D
a=aD ,c=0
s = 0)
× Pr(La=aY ,c=0AY ,s = lAY ,s | D
a=aY ,c=0
s = 0, L
a=aY ,c=0
s−1 = ls−1, L
a=aY ,c=0
AD ,s
= lAD ,s)
× Pr(La=aD ,c=0AD ,s = lAD,s | D
a=aD ,c=0
s = 0, L
a=aD ,c=0
s−1 = ls−1).(28)
Note that for s ≥ 0, invoking exchangeability and positivity,
Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls, D
a=aD,c=0
s = 0)
=Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls, D
a=aD,c=0
s = 0, D0 = C0 = 0, L0)
=
Pr(Da=aD ,c=0s+1 = 0, L
a=aD ,c=0
s = ls | D0 = C0 = 0, L0, A = aD)
Pr(Da=aD ,c=0s = 0, L
a=aD ,c=0
s = ls | D0 = C0 = 0, L0, A = aD)
=
Pr(Da=aD ,c=0s+1 = 0, L
a=aD ,c=0
s = ls | D0 = C1 = 0, L0, A = aD)
Pr(Da=aD ,c=0s = 0, L
a=aD ,c=0
s = ls | D0 = C1 = 0, L0, A = aD)
=Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls, D
a=aD,c=0
s = 0, D0 = C1 = 0, L0 = l0, A = aD)
Using consistency and positivity:
=Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls, D
a=aD,c=0
s = 0, D1 = C1 = 0, L1 = l1, A = aD),
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and arguing iteratively using exchangeability, consistency and the positivity conditions,
we find that
Pr(Da=aD ,c=0s+1 = 0 | L
a=aD ,c=0
s = ls, D
a=aD ,c=0
s = 0)
=Pr(Ds+1 = 0 | Ls = ls, Ds = Cs = 0, A = aD),(29)
and an analogous argument shows that
Pr(La=aY ,c=0AY ,s+1 = lAY ,s+1 | L
a=aY ,c=0
AD ,s+1
= lAD,s+1, L
a=aY ,c=0
s = ls, D
a=aY ,c=0
s+1 = 0)
=Pr(LAY ,s+1 = lAY ,s+1 | LAD ,s+1 = lAD,s+1, Ls = ls, Ds+1 = Cs = 0, A = aY ),(30)
and
Pr(La=aD ,c=0AD ,s+1 = lAD,s+1 | L
a=aD ,c=0
s = ls, D
a=aD ,c=0
s+1 = 0)
=Pr(LAD ,s+1 = lAD,s+1 | Ls = ls, Ds+1 = Cs = 0, A = aD).(31)
Similarly,
E(Y aY ,aD ,c=0 | DaY ,aD,c=0K+1 = 0, L
aY ,aD,c=0
K = lK)
=E(Y aY ,aD ,c=0 | DaY ,aD,c=0K+1 = 0, L
aY ,aD,c=0
K = lK , L0 = l0, C0 = D0 = 0, A = aY )
=E(Y a=aY ,c=0 | Da=aY ,c=0K+1 = 0, L
a=aY ,c=0
K = lK , L0 = l0, C0 = D0 = 0, A = aY )
=
∑
y
y Pr(Y a=aY ,c=0 = y | Da=aY ,c=0K+1 = 0, L
a=aY ,c=0
K = lK , L0 = l0, C0 = D0 = 0, A = aY ),
and we can then argue iteratively using exchangeability, consistency and positivity, to
find that
Pr(Y a=aY ,c=0 = y | Da=aY ,c=0K+1 = 0, L
a=aY ,c=0
K = lK , L0 = l0, C0 = D0 = 0, A = aY )
=Pr(Y = y | Dk+1 = Ck+1 = 0, LK = lK , A = aY ).
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Hence,
E(Y aY ,aD,c=0 | DaY ,aD ,c=0K+1 = 0, L
aY ,aD ,c=0
K = lK)
=E(Y | DK+1 = CK+1 = 0, LK = lK , A = aY ).(32)
The proof is completed by substituting the counterfactual terms in (26) with the observed
terms (29)-(32), using expressions (27) and (28). 
The identification formula in Theorem 1 also follows from the general algorithm in
Malinsky et al [22].
A.1. Alternative representation of the identification formula.
Theorem 2. An algebraically equivalent version of the identification formula (25) in the
presence of censoring is
E[WC,K(aY )WD,K(aY , aD)WLAD ,K(aY , aD)(1−DK+1)Y | A = aY ]
E[WC,K(aY )WD,K(aY , aD)WLAD ,K(aY , aD)(1−DK+1) | A = aY ]
,(33)
where
WD,K(aY , aD) =
∏k
j=0 Pr(Dj+1 = 0 | Cj+1 = Dj = 0, Lj, A = aD)∏k
j=0Pr(Dj+1 = 0 | Cj+1 = Dj = 0, Lj , A = aY )
,
WLAD ,k(aY , aD) =
∏k
j=0 Pr(LAD,j = lAD,j | Cj = Dj = 0, Lj−1, A = aD)∏k
j=0Pr(LAD ,j = lAD ,j | Cj = Dj = 0, Lj−1, A = aY )
,
WC,K(aD) =
I(Ck+1 = 0)∏k
j=0 Pr(Cj+1 = 0 | Cj = Dj = 0, Lj , A = aD)
.
Selecting the partition LAY ,k+1 = Lk+1 and LAD ,k+1 = ∅, consistent with identification
under AY partial isolation (see Stensrud et al. [12, Appendix C]), the weights in for-
mula (33) reduce to W1,K(aY , aD) defined in Section 8 of the main text in the absence of
censoring.
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Proof. Define
W ′C,k(a) =
1∏k
j=0Pr(Cj+1 = 0 | Cj = Dj = 0, Lj, A = a)
.
We have
E[WC,K(aY )WD,K(aY , aD)WLAD ,K(aY , aD)(1−DK+1)Y | A = aY ]
=
∑
y
∑
lk
∑
dk+1
∑
ck+1
[Pr(Y = y, dk+1, ck+1, Lk = lk | A = aY )W
′
C,k(a)WD,k(aY , aD)WLAD ,k(aY , aD)
× y(1− dk+1)(1− ck+1)]
=
∑
y
∑
lk
y[Pr(Y = y, Lk = lk, Dk+1 = Ck+1 = 0 | A = aY )W
′
C,k(aY )WD,k(aY , aD)WLAD ,k(aY , aD)]
=
∑
y
∑
lk
y[Pr(Y = y | Dk+1 = Ck+1 = 0, Lk = lk, A = aY ) Pr(Dk+1 = 0 | Ck+1 = Dk = 0, Lk = lk, A = aY )
× Pr(Ck+1 = 0 | Dk = Ck = 0, Lk = lk, A = aY ) Pr(Lk = lk | Ck = Dk = 0, A = aY )
× Pr(Dk = Ck = 0 | A = aY )
×W ′C,k(aY )WD,k(aY , aD)WLAD ,k(aY , aD)]
=
∑
y
∑
lk
y[Pr(Y = y | Dk+1 = Ck+1 = 0, Lk = lk, A = aY ) Pr(Dk+1 = 0 | Ck+1 = Dk = 0, Lk = lk, A = aY )
× Pr(Ck+1 = 0 | Dk = Ck = 0, Lk = lk, A = aY ) Pr(Lk = lk | Ck = Dk = 0, Lk−1 = lk−1, A = aY )
× Pr(Dk = Ck = 0, Lk−1 = lk−1 | A = aY )
×W ′C,k(aY )WD,k(aY , aD)WLAD ,k(aY , aD)].
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We use laws of probability to express Pr(Dk = Ck = 0, Lk−1 = lk−1 | A = aY ) as
Pr(Dk = 0 | Ck = Dk−1 = 0, Lk−1 = lk−1, A = aY )
× Pr(Ck = 0 | Dk−1 = Ck−1 = 0, Lk−1 = lk−1, A = aY )
× Pr(Lk−1 = lk−1 | Ck−1 = Dk−1 = 0, Lk−2 = lk−2, A = aY )
× Pr(Dk−1 = 0, Lk−2 = lk−2, Ck−1 = 0 | A = aY ).
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Arguing iteratively we have
E[WC,k(aY )WD,k(aY , aD)WLAD ,k(aY , aD)Y (1−Dk+1) | A = aY ]
=
∑
y
∑
lk
y
[
Pr(Y = y | Dk+1 = Ck+1 = 0, Lk = lk, A = aY )
k∏
j=0
[
Pr(Dj+1 = 0 | Cj+1 = Dj = 0, Lj = lj , A = aY )
× Pr(Cj+1 = 0 | Dj = Cj = 0, Lj = lj, A = aY )
× Pr(Lj = lj | Cj = Dj = 0, Lj−1 = lj−1, A = aY )]
×W ′C,k(aY )WD,k(aY , aD)WLAD ,k(aY , aD)
]
=
∑
y
∑
lk
y
[
Pr(Y = y | Dk+1 = Ck+1 = 0, Lk = lk, A = aY )
k∏
j=0
[
Pr(Dj+1 = 0 | Cj+1 = Dj = 0, Lj = lj , A = aY )
× Pr(Cj+1 = 0 | Dj = Cj = 0, Lj = lj, A = aY )
× Pr(LAY ,j = lAY ,j | Cj = Dj = 0, Lj−1 = lj−1, LAD ,j = lAD,j , A = aY )
× Pr(LAD ,j = lAD ,j | Cj = Dj = 0, Lj−1 = lj−1, A = aY )
]
×W ′C,k(aY )WD,k(aY , aD)WLAD ,k(aY , aD)
]
,
where we used that Lk = (LAY ,j, LAD ,j) in the second equality.
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By plugging in the expressions for the weightsW ′C,k(aY ),WD,k(aY , aD) andWLAD ,k(aY , aD)
we obtain
=
∑
y
∑
lk
y
[
Pr(Y = y | Dk+1 = Ck+1 = 0, Lk = lk, A = aY )
k∏
j=0
[
Pr(Dj+1 = 0 | Cj+1 = Dj = 0, Lj = lj , A = aD)
× Pr(LAY ,j = lAY ,j | Cj = Dj = 0, Lj−1 = lj−1, LAD ,j = lAD,j , A = aY )
× Pr(LAD ,j = lAD ,j | Cj = Dj = 0, Lj−1 = lj−1, A = aD)
]]
.
We can use analogous steps to find an expression for the denominator,
E][WC,K(aY )WD,K(aY , aD)WLAD ,K(aY , aD)(1−DK+1) | A = aY ]
=
∑
lk
[ k∏
j=0
[
Pr(Dj+1 = 0 | Cj+1 = Dj = 0, Lj = lj , A = aD)
× Pr(LAY ,j = lAY ,j | Cj = Dj = 0, Lj−1 = lj−1, lAD ,j, A = aY )
× Pr(LAD ,j = lAD ,j | Cj = Dj = 0, Lj−1 = lj−1, A = aD)
]]
,
which completes the proof. 
Appendix B. Non-parametric influence function and doubly robust
estimators
Here we derive the non-parametric influence function for the identification formula (12)
from the main text. This function equals E(Y aY ,aD | DaY ,aDK+1 = 0) for aY 6= aD under the
modified treatment assumption, AY partial isolation, the absence of censoring and the
identifying conditions of Section 7.
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Theorem 3. The nonparametric influence function of the estimand (12) under a data
generating model p is
1
Ep(1−DK+1 | A = aD)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)Ep(Y | DK+1 = 0, A = aY , LK)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A
(L1, 0 | L0, aD)
fL1,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)[Y − Ep(Y | DK+1 = 0, A, LK)]
−
I(A = aD)(1−DK+1)
P (DK+1 = 0, A = aD)
Ep(Y | DK+1 = 0, A = aY , LK)fL1,DK+1|L0,A(L1, 0 | L0, aD)fL0(L0)
}
.
(34)
Proof. We follow previous results on nonparametric influence functions [25, 35, 36, 37, 38].
Let ν1(pt) denote the nonparametric influence function for the estimand (12) under a law
pt, where t ∈ [0, 1] indexes a regular parametric submodel such that p0 is the true data
generating model. Note that we can re-express (12) as
ν(pt) =
α(pt)
β(pt)
=
E(E(Y | DK+1 = 0, LK , A = aY )(1−DK+1) | A = aD)
E(1−DK+1 | A = aD)
.
To derive the influence function for our target parameter ν(pt) = h(α(pt), β(pt)) =
α(pt)
β(pt)
,
we apply derivation by parts,
ν1(pt) =
1
β(pt)
α1(pt)−
α(pt)
[β(pt)]2
β1(pt)
=
1
β(pt)
(α1(pt)− ν(pt)β
1(pt)).
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First,
dα(pt)
dt
∣∣∣
t=0
=
d
dt
Ept(Ep0
(
Y | DK+1 = 0, A = aY , LK
)
(1−DK+1) | A = aD)
∣∣∣
t=0
+ Ep0
[
d
dt
Ept(Y | DK+1 = 0, A = aY , LK)
∣∣∣
t=0
(1−DK+1) | A = aD
]
=Ep0
[
Ep0(Y | DK+1 = 0, A = aY , LK)(1−DK+1)gDK+1,LK |A=aD | A = aD
]
+ Ep0
[
Ep0
[
Y gY |DK+1,LK ,A=aY | DK+1 = 0, A = aY , LK
]
(1−DK+1) | A = aD
]
=Ep0([Ep0(Y | DK+1 = 0, A = aY , LK)(1−DK+1)
− Ep0(Ep0(Y | DK+1 = 0, A = aY , LK)(1−DK+1) | A = aD)]× gDK+1,LK |A=aD | A = aD)
+ Ep0(Ep0([Y − Ep0(Y | DK+1 = 0, A = aY , LK)]gY |DK+1,LK ,A=aY | DK+1 = 0, A = aY , LK)
× (1−DK+1) | A = aD)
=Ep0
[
I(A = aD)
P (A = aD)
{
Ep0
[
Y | DK+1 = 0, A = aY , LK
]
(1−DK+1)
− Ep0
[
I(A = aD)
P (A = aD)
Ep0(Y | DK+1 = 0, A = aY , LK)(1−DK+1)
]}
× gDK+1,LK |A
]
+ Ep0
[
I(A = aD)
P (A = aD)
Ep0(
I(A = aY )
P (A = aY | DK+1 = 0, LK)
[Y − Ep0(Y | DK+1 = 0, A, LK)]
× gY |DK+1,LK ,A | DK+1 = 0, LK)(1−DK+1)
]
=
1
P (A = aD)
Ep0
[
I(A = aD)
{
Ep0(Y | DK+1 = 0, A = aY , LK)(1−DK+1)
−Ep0
[
I(A = aD)
P (A = aD)
Ep0(Y | DK+1 = 0, A = aY , LK)(1−DK+1)
]}
×(gY |DK+1,LK ,A + gDK+1,LK |A + gA)︸ ︷︷ ︸
Diff in exp { } is mean 0 given A
]
+Ep0
[
I(A = aD)
P (A = aD)
Ep0
{ I(A = aY )(1−DK+1)
P (A = aY | DK+1 = 0, LK)P (DK+1 = 0 | LK)
[Y − Ep0(Y | DK+1 = 0, A, LK)]
× gY |DK+1,LK ,A | LK
}
(1−DK+1)
]
.
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Hereby all expected values E(·) are taken with respect to p0, so we omit the subscript.
Consider the last line in the expression above,
E
[
I(A = aD)
P (A = aD)
E
( I(A = aY )(1−DK+1)
P (A = aY | DK+1 = 0, LK)P (DK+1 = 0 | LK)
[Y − E(Y | DK+1 = 0, A, LK)]
× gY |DK+1,LK ,A | LK
)
(1−DK+1)
]
=E
[
I(A = aD)
P (A = aD)
(1−DK+1)E
( I(A = aY )(1−DK+1)
P (A = aY , DK+1 = 0 | LK)
[Y − E(Y | DK+1 = 0, A, LK)]
× gY |DK+1,LK ,A | LK
)]
=E
[
P (A = aD, DK+1 = 0 | LK)
P (A = aD)
I(A = aY )(1−DK+1)
P (A = aY , DK+1 = 0 | LK)
[Y − E(Y | DK+1 = 0, A, LK)]
× gY |DK+1,LK ,A
]
=E
[
P (A = aD, DK+1 = 0 | LK)
P (A = aD)
I(A = aY )(1−DK+1)
P (A = aY , DK+1 = 0 | LK)
[Y − E(Y | DK+1, A, LK)]
×(gY |DK+1,LK ,A + gDK+1,LK ,A)︸ ︷︷ ︸
Expectation in [ ] is mean 0 given DK+1, LK , A
]
.
Thus,
α1(p0) =
I(A = aD)
P (A = aD)
[
E
(
Y | DK+1 = 0, A = aY , LK
)
(1−DK+1)
− E
( I(A = aD)
P (A = aD)
E
(
Y | DK+1 = 0, A = aY , LK
)
(1−DK+1)
)]
+
P (A = aD, DK+1 = 0 | LK)
P (A = aD)
I(A = aY )(1−DK+1)
P (A = aY , DK+1 = 0 | LK)
[Y − E(Y | DK+1 = 0, A, LK)].
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We can derive the influence function β1(p) of the denominator using a similar but
simpler argument for dβ(pt)
dt
∣∣∣
t=0
to find that
β1(p0) =
I(A = aD)
P (A = aD)
[P (DK+1 = 1 | A)−DK+1]
=
I(A = aD)
P (A = aD)
[(1−DK+1)− P (DK+1 = 0 | A)].
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Finally, using the above results and derivation by parts we have
ν1(p) =
1
β(p)
×
{
I(A = aD)
P (A = aD)
[
Ep(Y | DK+1 = 0, A = aY , LK)(1−DK+1)
− Ep
[
I(A = aD)
P (A = aD)
Ep(Y | DK+1 = 0, A = aY , LK)(1−DK+1)
]]
+
P (A = aD, DK+1 = 0 | LK)
P (A = aD)
I(A = aY )(1−DK+1)
P (A = aY , DK+1 = 0 | LK)
[Y − Ep(Y | DK+1 = 0, A, LK)]
−
I(A = aD)
P (A = aD)
[(1−DK+1)− P (DK+1 = 0 | A)]
×
Ep(Ep(Y | DK+1 = 0, A = aY , LK)(1−DK+1) | A = aD)
P (DK+1 = 0 | A = aD)
}
=
1
β(p)
×
{
I(A = aD)
P (A = aD)
[
(1−DK+1)Ep(Y | DK+1 = 0, A = aY , LK)
− Ep
[
I(A = aD)
P (A = aD)
(1−DK+1)Ep(Y | DK+1 = 0, A = aY , LK)
]]
+
P (A = aD, DK+1 = 0 | LK)
P (A = aD)
I(A = aY )(1−DK+1)
P (A = aY , DK+1 = 0 | LK)
[Y − Ep(Y | DK+1 = 0, A, LK)]
−
I(A = aD)
P (A = aD)
[
(1−DK+1)Ep(
I(A = aD)(1−DK+1)
P (A = aD)P (DK+1 = 0 | A = aD)
Ep(Y | DK+1 = 0, A = aY , LK))
− Ep
[
I(A = aD)(1−DK+1)
P (A = aD)
Ep(Y | DK+1 = 0, A = aY , LK)
]]}
=
1
β(p)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)Ep(Y | DK+1 = 0, A = aY , LK)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A(L1, 0 | L0, aD)
fL1,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)[Y − Ep(Y | DK+1 = 0, A, LK)]
−
I(A = aD)
P (A = aD)
(1−DK+1)Ep
[
I(A = aD)(1−DK+1)
P (DK+1 = 0, A = aD)
Ep(Y | DK+1 = 0, A = aY , LK)
]}
=
1
β(p)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)Ep(Y | DK+1 = 0, A = aY , LK)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A(L1, 0 | L0, aD)
fL1,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)[Y − Ep(Y | DK+1 = 0, A, LK)]
−
I(A = aD)(1−DK+1)
P (DK+1 = 0, A = aD)
Ep(Y | DK+1 = 0, A = aY , LK)fL1,DK+1|L0,A(L1, 0 | L0, aD)fL0(L0)
}
,
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where the last line in the last equality follows from iterative expectations because
Ep
[
I(A = aD)(1−DK+1)
P (DK+1 = 0, A = aD)
| LK
]
=
Ep[I(A = aD)(1−DK+1) | LK ]
P (A = aD)P (DK+1 = 0 | A = aD)
=
fL1,DK+1|L0,A(L1, 0 | L0, aD)
P (DK+1 = 0 | A = aD)fL1(L1)
.

B.1. Constructing a doubly robust estimator. Let superscript ∼ denote an estima-
tor. The influence function (34) motivates the following M-estimator νˆdr,aY ,aD , which is
a solution to
n∑
i=1
Uˆi(νaY ,aD) = 0,
where
U(νaY ,aD) =
1
β(p)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)E(Y | DK+1 = 0, A = aY , LK)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A
(L1, 0 | L0, aD)
fL1,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)[Y − E(Y | DK+1 = 0, A, LK)]
}
− νaY ,aD ,
and, analogously, Uˆ(νaY ,aD) is defined as above but evaluated under the estimators E˜(Y |
DK+1 = 0, A, LK), f˜L1,DK+1|L0,A(L1, 0 | L0, A) and β˜(pt).
Note that the estimator νˆdr,aY ,aD is equivalent to the one step estimator derived from
the influence function ν1
P˜
, specifically νˆdr,aY ,aD = ν(P˜ ) + Pn(ν
1
P˜
) where ν(P˜ ) is the naive
plug-in estimator of νaY ,aD and Pn(·) is the empirical law. This can be seen by the
following argument: let θP˜ be the last term of ν
1
P˜
in (34), and note that Pn(θP˜ ) = ν(P˜ ),
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that is,
Pn(θP˜ )
=Pn
(
I(A = aD)(1−DK+1)
β˜P˜ (DK+1 = 0, A = aD)
E˜(Y | DK+1 = 0, A = aY , LK)P˜L1,DK+1|L0,A(L1, 0 | L0, aD)f˜L0(L0)
)
=Pn
(
1
β˜
E˜(Y | DK+1 = 0, A = aY , LK)P˜L1,DK+1|L0,A(L1, 0 | L0, aD)f˜L0(L0)
)
,
where β˜(p) are P˜ (DK+1 = 0, A = aD) are empirical averages.
Given that β(p) can be estimated consistently with the sample average β˜ = En(1 −
DK+1 | A = aD), in the next section we show that νˆdr,aY ,aD is doubly robust, in the sense
that E(Uˆ(νaY ,aD)) = 0 if either E(Y | DK+1 = 0, A, LK) or fL1,DK+1|L0,A(L1, 0 | L0, a) is
consistently estimated by E˜(Y | DK+1 = 0, A, LK) or f˜L1,DK+1|L0,A(L1, 0 | L0, a) but not
necessarily both. We show this in Section B.2.
B.2. Proof of doubly robustness. First we express E(Uˆ(νaY ,aD) + νaY ,aD)
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E(Uˆ(νaY ,aD ) + νaY ,aD )
=
1
β˜
×
{
E[
I(A = aD)
P (A = aD)
(1−DK+1)E˜(Y | DK+1 = 0, A = aY , LK)]
+E[
I(A = aY )
P (A = aY )
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
(1 −DK+1)[Y − E˜(Y | DK+1 = 0, A, LK)]]
}
.
=
1
β˜
×
{
E[E[
I(A = aD)
P (A = aD)
(1 −DK+1)E˜(Y | DK+1 = 0, A = aY , LK) | LK ]]
+E[E[
I(A = aY )
P (A = aY )
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)[Y − E˜(Y | DK+1 = 0, A, LK)] | LK ]]]
}
.
=
1
β˜
×
{
E[E˜(Y | DK+1 = 0, A = aY , LK)E[
I(A = aD)
P (A = aD)
(1−DK+1) | LK ]]
+E
[ 1
P (A = aY )
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
{E[I(A = aY )(1 −DK+1)Y | LK ]
− E[I(A = aY )(1 −DK+1)E˜(Y | DK+1 = 0, A, LK) | LK ]}
]}
.
=
1
β˜
×
{
E[E˜(Y | DK+1 = 0, A = aY , LK)
1
P (A = aD | L0)
P(DK+1 = 0, A = aD | LK)]
+E
[ 1
P (A = aY )
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
{E[I(A = aY )(1 −DK+1)E(Y | DK+1 = 0, A, LK) | LK ]
− E[I(A = aY )(1 −DK+1)E˜(Y | DK+1 = 0, A, LK) | LK ]}
]}
.
=
1
β˜
×
{
E
[
E˜(Y | DK+1 = 0, A = aY , LK)
fL
1
,DK+1|L0,A
(L1, 0 | L0, aD)
fL
1
(L1)
]
+E
[
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
E[
I(A = aY )
P (A = aY )
(1−DK+1){E(Y | DK+1 = 0, A, LK)− E˜(Y | DK+1 = 0, A, LK)} | LK ]
]}
.
From the final expression above, we see that the estimator is doubly robust. First,
if E˜(Y | DK+1 = 0, A, LK) is correctly specified but f˜L1,DK+1|L0,A(L1, 0 | L0, aD) is not
neccessarily correctly specified, then the second line in the final equality above is 0 and
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the first line is the estimand of interest, that is,
=
1
β˜
×
{
E
[
E˜(Y | DK+1 = 0, A = aY , LK)
fL
1
,DK+1|L0,A
(L1, 0 | L0, aD)
fL
1
(L1)
]
+E
[ f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
× E[
I(A = aY )
P (A = aY )
(1−DK+1) {E(Y | DK+1 = 0, A, LK)− E˜(Y | DK+1 = 0, A, LK)}︸ ︷︷ ︸
=0 ∀lk∈Lk
| LK ]
]}
.
=
1
β˜
×
∑
lk
[
E˜(Y | DK+1 = 0, A = aY , LK = lK)fLK ,DK+1|A(lk, 0 | aD)
]
.
Second, if f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD) is correctly specified but not necessarily E˜(Y | DK+1 = 0, A, LK)
is correctly specified, then
=
1
β˜
×
{
E
[
E˜(Y | DK+1 = 0, A = aY , LK)
fL
1
,DK+1|L0,A
(L1, 0 | L0, aD)
fL
1
(L1)
]
+E
[ f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
E[
I(A = aY )
P (A = aY | L0)
× (1−DK+1){E(Y | DK+1 = 0, A, LK)− E˜(Y | DK+1 = 0, A, LK)} | LK ]
]}
.
=
1
β˜
×
{∑
lk
[
E˜(Y | DK+1 = 0, A = aY , LK = lk)fLK ,DK+1|A(lK , 0 | aD)
]
+E
[
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
fL
1
,DK+1|L0,A
(L1, 0 | L0, aY )
fL
1
(L1)
E(Y | DK+1 = 0, A, LK) | LK
]
.
− E
[
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
f˜L
1
,DK+1|L0,A(L1, 0 | L0, aY )
fL
1
,DK+1|L0,A
(L1, 0 | L0, aY )
fL
1
(L1)
E˜(Y | DK+1 = 0, A, LK)
]}
.
=
1
β˜
×
{∑
lK
[
E˜(Y | DK+1 = 0, A = aY , LK = lk)fLK ,DK+1|A(lk, 0 | aD)
]
+
∑
lk
[
E(Y | DK+1 = 0, A = aY , LK = lk)f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
]
−
∑
lk
[
E˜(Y | DK+1 = 0, A = aY , LK = lK)f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
]}
=
1
β˜
∑
lk
[
E(Y | DK+1 = 0, A = aY , LK = lK)f˜L
1
,DK+1|L0,A(L1, 0 | L0, aD)
]
.
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Appendix C. Censoring in the data analysis of Section 9
In our illustrative data example in Section 9, there were no missing values for (DK+1, LK , A),
K = 11, but some subjects had missing values for Y ; that is, quality of life at 12 months
of follow-up was unknown in some individuals. This coincides with the censored data
structure of Appendix A for the special case where C11 = 0 and a modified temporal
order assumption in interval K +1 such that DK+1 precedes C ≡ CK+1. In this case, the
identifying function (25) reduces to
ν(p) =
Ep
(
Ep
(
Y (1−C)
Pr(C=0|DK+1=0,LK ,A=aY )
| DK+1 = 0, LK , A = aY
)
(1−DK+1) | A = aD
)
Ep(1−DK+1 | A = aD)
,
(35)
consistent with identification under AY partial isolation.
To fit the outcome regression estimator νˆor,aY ,aD , we used the estimator described in
Section 8, but the outcome regression was restricted to the uncensored observations.
To fit the weighted estimator νˆipw,aY ,aD in the application in Section 9 the main text,
we adjusted for censoring using the censoring weights WC,K from Appendix A.1 based on
the following model for the weight denominator:
logit[Pr(C = 1 | D12 = 0, A, L0, Lk;αC)]
= αC,0 + αC,1A+ α
′
C,2L0 + αC,3L11.(36)
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In this case, we used a modified doubly robust estimator νˆdr,aY ,aD based on the non-
parametric influence function for (35),
1
Ep(1−DK+1 | A = aD)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)Ep(Y | DK+1 = C = 0, A = aY , LK)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A(L1, 0 | L0, aD)
fL1,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)(1− C)
[Y − Ep(Y | DK+1 = C = 0, A, LK)]
Pr(C = 0 | DK+1 = 0, LK , A = aY )
−
I(A = aD)(1−DK+1)
P (DK+1 = 0, A = aD)
Ep(Y | DK+1 = C = 0, A = aY , LK)fL1,DK+1|L0,A(L1, 0 | L0, aD)fL0(L0)
}
,
which is derived using straightforward extensions of the arguments in Appendix B. This
motivates the estimating function
U(νaY ,aD) =
1
β(p)
×
{
I(A = aD)
P (A = aD)
(1−DK+1)E(Y | DK+1 = C = 0, A = aY , LK)
+
I(A = aY )
P (A = aY )
fL1,DK+1|L0,A(L1, 0 | L0, aD)
fL1,DK+1|L0,A(L1, 0 | L0, aY )
(1−DK+1)(1− C)
×
[Y − Ep(Y | DK+1 = C = 0, A, LK)]
Pr(C = 0 | DK+1 = 0, LK , A = aY )
}
− νaY ,aD ,
and, similar to Section B.1, we define Uˆ(νaY ,aD) as above but evaluated under the esti-
mators E˜(Y | DK+1 = 0, C = 0, A, LK), f˜L1,DK+1|L0,A(L1, 0 | L0, A), P˜r(C = 0 | DK+1 =
0, LK , A = aY ) and β˜(pt). Let νˆdr,aY ,aD be the solution to the estimating equation∑n
i=1 Uˆi(νaY ,aD) = 0. This estimator is consistent if E˜(Y | DK+1 = 0, C = 0, A, LK)
is correctly specified, or if both f˜L1,DK+1|L0,A(L1, 0 | L0, aD) and P˜r(C = 0 | DK+1 =
0, LK , A = aY ) are correctly specified. We computed this estimator under the model (36)
above for censoring and the models specified in Section 9, but with the outcome model
restricted to uncensored individuals.
